Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy’’

被引：0
|
作者：
Samantha Bowyer
Prashanth Prithviraj
Paul Lorigan
James Larkin
Grant McArthur
Victoria Atkinson
Michael Millward
Muoi Khou
Stefan Diem
Sangeetha Ramanujam
Ben Kong
Elizabeth Liniker
Alexander Guminski
Phillip Parente
Miles C Andrews
Sagun Parakh
Jonathan Cebon
Georgina V Long
Matteo S Carlino
Oliver Klein
机构：
[1] Rockingham General Hospital,Department of Medical Oncology
[2] School of Medicine and Pharmacology,Department of Medical Oncology
[3] University of Western Australia,undefined
[4] Olivia Newton-John Cancer Centre,undefined
[5] Austin Hospital,undefined
[6] Olivia Newton-John Cancer Research Institute,undefined
[7] The Christie NHS Foundation Trust and University of Manchester,undefined
[8] Royal Marsden Hospital NHS Foundation Trust,undefined
[9] Peter MacCallum Cancer Centre,undefined
[10] Princess Alexandra Hospital,undefined
[11] Greenslopes Private Hospital,undefined
[12] Sir Charles Gairdner Hospital,undefined
[13] Westmead Hospital,undefined
[14] Melanoma Institute Australia,undefined
[15] Box Hill Hospital,undefined
[16] University of Sydney,undefined
来源：
British Journal of Cancer | 2017年 / 116卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：e15 / e15
相关论文
共 50 条
  • [1] Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''
    Bowyer, Samantha
    Prithviraj, Prashanth
    Lorigan, Paul
    Larkin, James
    McArthur, Grant
    Atkinson, Victoria
    Millward, Michael
    Khou, Muoi
    Diem, Stefan
    Ramanujam, Sangeetha
    Kong, Ben
    Liniker, Elizabeth
    Guminski, Alexander
    Parente, Phillip
    Andrews, Miles C.
    Parakh, Sagun
    Cebon, Jonathan
    Long, Georgina V.
    Carlino, Matteo S.
    Klein, Oliver
    [J]. BRITISH JOURNAL OF CANCER, 2017, 116 (08) : e15 - e15
  • [2] Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'
    Imafuku, Keisuke
    Yoshino, Koji
    Yamaguchi, Kei
    Tsuboi, Satoshi
    Ohara, Kuniaki
    Hata, Hiroo
    [J]. BRITISH JOURNAL OF CANCER, 2017, 116 (08) : e14 - e14
  • [3] Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy’
    Keisuke Imafuku
    Koji Yoshino
    Kei Yamaguchi
    Satoshi Tsuboi
    Kuniaki Ohara
    Hiroo Hata
    [J]. British Journal of Cancer, 2017, 116 : e14 - e14
  • [4] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
    Bowyer, S.
    Prithviraj, P.
    Lorigan, P.
    Larkin, J.
    McArthur, G.
    Atkinson, V.
    Millward, M.
    Khou, M.
    Diem, S.
    Ramanujam, S.
    Kong, B.
    Liniker, E.
    Guminski, A.
    Parente, P.
    Andrews, M. C.
    Parakh, S.
    Cebon, J.
    Long, G. V.
    Carlino, M. S.
    Klein, O.
    [J]. BRITISH JOURNAL OF CANCER, 2016, 114 (10) : 1084 - 1089
  • [5] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
    S Bowyer
    P Prithviraj
    P Lorigan
    J Larkin
    G McArthur
    V Atkinson
    M Millward
    M Khou
    S Diem
    S Ramanujam
    B Kong
    E Liniker
    A Guminski
    P Parente
    M C Andrews
    S Parakh
    J Cebon
    G V Long
    M S Carlino
    O Klein
    [J]. British Journal of Cancer, 2016, 114 : 1084 - 1089
  • [6] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy
    Prithviraj, Prashanth
    McArthur, Grant A.
    Atkinson, Victoria
    Parente, Phillip
    Andrews, Miles Cameron
    Parakh, Sagun
    Cebon, Jonathan S.
    Klein, Oliver
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
    Lipson, Evan J.
    Drake, Charles G.
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (22) : 6958 - 6962
  • [8] Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma
    Reddy, Swathi B.
    Possick, Jennifer D.
    Kluger, Harriet M.
    Galan, Anjela
    Han, Dale
    [J]. JOURNAL OF IMMUNOTHERAPY, 2017, 40 (08) : 307 - 311
  • [9] Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies
    Robert, Caroline
    Mateus, Christina
    [J]. BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2014, 198 (02): : 297 - 308
  • [10] Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management
    Savoia, Paola
    Astrua, Chiara
    Fava, Paolo
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (05) : 1092 - 1101
12345